Patients With Metastatic Castration Resistant Prostate Cancer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patients with metastatic castration resistant prostate cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patients With Metastatic Castration Resistant Prostate Cancer Today - Breaking & Trending Today

177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic Castration-Resistant Prostate Cancer

Treatment with 177Lu-PNT2002 resulted in a significant improvement in radiographic progression-free survival vs abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer whose disease had progressed on an androgen receptor pathway inhibitor. ....

United States , Kim Chi , Kaplan Meier , Prostate Cancer Clinical Trials Working Group , Lantheus Holdings Inc , Common Terminology Criteria , Adverse Events , Lantheus Holdings , Treatment With 177lu Pnt2002 , Patients With Metastatic Castration Resistant Prostate Cancer , Splash Study , Bc Cancer ,

Dr Laccetti on PSA Responses With Masofaniten Plus Enzalutamide in mCRPC

Andrew Laccetti, MD, MS, discusses phase 1 findings from a phase 1/2 trial investigating masofaniten in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer. ....

Andrew Laccetti , Memorial Sloan Kettering Cancer Center , Masofaniten In Combination With Enzalutamide , Patients With Metastatic Castration Resistant Prostate Cancer ,

Dr Shen on the Tolerability and Efficacy of ARX517 in mCRPC

John Shen, MD, discusses unique features associated with the use of the prostate-specific membrane antigen–directed antibody-drug conjugate ARX517 in patients with metastatic castration-resistant prostate cancer and highlights early efficacy and safety findings with this agent. ....

John Shen , University Of California Los Angeles Health Encino Cancer Care , Patients With Metastatic Castration Resistant Prostate Cancer ,

Pembrolizumab Plus Enzalutamide Delivers No rPFS or OS Benefits in mCRPC

Pembrolizumab plus enzalutamide provided no radiographic progression-free survival or overall survival improvements vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer. ....

United States , Pembrolizumab Keytruda , Julien Graff , Oregon Health Science University Knight Cancer Institute , Oregon Health , Science University Knight Cancer Institute , Pembrolizumab Plus Enzalutamide , Patients With Metastatic Castration Resistant Prostate Cancer , Keynote 641 Trial , Oregon Health Amp Science University Knight Cancer Institute ,

Lack of Clinical Benefit Leads to End of Development for Etrumadenant in mCRPC

The development of etrumadenant as a potential treatment option for patients with metastatic castration-resistant prostate cancer will be discontinued after data from the phase 1/2 ARC-6 trial did not demonstrate a sufficient clinical benefit for etrumadenant plus zimberelimab and docetaxel compared with docetaxel alone. ....

Accessed August , Development Of Etrumadenant , Patients With Metastatic Castration Resistant Prostate Cancer , Arc 6 Trial , Etrumadenant Plus Zimberelimab And Docetaxel , Arc 9 Trial ,